Trials / Completed
CompletedNCT02095158
A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea
A Long-term Safety and Efficacy Study of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 440 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxymetazoline HCL Cream 1.0% | Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks. |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-08-01
- Completion
- 2015-09-01
- First posted
- 2014-03-24
- Last updated
- 2019-11-18
- Results posted
- 2016-09-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02095158. Inclusion in this directory is not an endorsement.